Days after announcing the first response rates from a Phase I/II trial of CAR T cell therapy AUTO1, Autolus raised $100.8 million in a follow-on offering.

On April 1 Autolus, a company in which Cancer Research UK has an equity position, said that after one month, CD19-targeting AUTO1 led to molecular complete responses in eight of nine evaluable patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL). At five months, six of 10 were alive and in molecular remission. There were no cases of grade 3 or higher cytokine release syndrome.

Read more here